MedTrace Logo

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121

NCT06025773 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-08-01

No results posted yet for this study

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-212-A in healthy subjects.

Conditions

  • Gastro Esophageal Reflux

Interventions

DRUG

Lansoprazole 15 mg

AD-2121 (Lansoprazole 15 mg), Oral, Capsule

DRUG

Lansoprazole 15mg/Calcium carbonate 600mg

AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-15
Primary Completion
2024-04-19
Completion
2024-04-19

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06025773 on ClinicalTrials.gov